2 October 2023 - Report tailored to reflect legislative specifications in the Inflation Reduction Act and subsequent CMS guidance regarding ...
27 September 2023 - Academic leader in HTA to rejoin ICER in November 2023. ...
25 September 2023 - Registration now open for 5 October “Early Insights” webinar. ...
25 September 2023 - Updates to methods and public meeting procedures reflect experience with previous framework, benchmarking with other HTA groups, ...
10 September 2023 - The quality-adjusted life-year (QALY) is an international standard in cost-effectiveness analysis. A known concern arises from the ...
26 July 2023 - Registration now open for 3 August “Early Insights” webinar. ...
25 July 2023 - Report will be subject of CTAF meeting in February 2024; draft scoping document open to public ...
5 July 2023 - Report will be subject of New England CEPAC meeting in February 2024; draft scoping document open ...
21 June 2023 - ICER’s third annual “Barriers to Fair Access” report will be published in November 2023. ...
5 June 2023 - Proposed updates reflect experience with current framework, benchmarking with other health technology assessment groups, and external stakeholder ...
25 May 2023 - Independent appraisal committee narrowly voted that currently available evidence for resmetirom is adequate to demonstrate a net ...
15 May 2023 - Report will be subject of Midwest CEPAC meeting in December 2023; draft scoping document open to ...
24 April 2023 - NICE, the Canadian Agency for Drugs and Technologies in Health and the US’s Institute for Clinical and ...
19 April 2023 - White bagging, brown bagging, and site of service policies developed by payers can reduce significant markup costs ...
17 April 2023 - Using best estimates from current data, ICER analyses suggest lecanemab would achieve common thresholds for cost-effectiveness if ...